Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447887 · ClinicalTrials.gov registry record · Phase 1
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02447887 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT02447887, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic information; using the study drug Ixazomib, they can promote necrotic cell death of RCC using interferon alpha - 2b. They hypothesize that the combination of ixazomib with IFN will lead to increased necrotic cell death in RCC tumors and consequent clinical benefit to patients. Patients will receive ixazomib capsules and pegylated IFN alfa 2b injection in this research study. Treatments will be given weekly and 4 weeks of treatment make up one cycle.
Interventions
- DRUG Ixazomib
- DRUG Pegylated IFN-alpha 2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-08-14 |
| Est. Completion | 2017-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447887
The ClinicalTrials.gov registry entry for NCT02447887 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ixazomib is the first listed.
NCT02447887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02447887 about?
NCT02447887 is a clinical study titled "Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)". This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic information; using the study drug Ixazomib, they can promote necrotic ...
What is the current status of trial NCT02447887?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-08-14. Estimated completion is 2017-04-25.
What interventions are being tested in trial NCT02447887?
The interventions under investigation include: Ixazomib (DRUG), Pegylated IFN-alpha 2b (DRUG).
Who is sponsoring clinical trial NCT02447887?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.